
|Videos|October 20, 2017
The Importance of CNS Activity in Agents for NSCLC
Author(s)Alexander Drilon, MD
Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the importance of central nervous system (CNS) activity in agents for the treatment of non–small cell lung cancer (NSCLC).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Phase 3 LAGOON Trial Fails to Confirm Survival Benefit of Lurbinectedin in Relapsed SCLC
2
KRAS-Mutant Lung Cancer: ASCO 2026 Highlights & Emerging Therapies
3
The Gap Between What Oncologists Have Been Prescribing and What the ROS1 Data Now Supports
4
Talquetamab Plus Daratumumab Improves PFS vs SOC in R/R Multiple Myeloma
5







































